Actimmune interferon gamma-1b: Interim Phase IIb data

Forty-eight week, interim data from an open-label, U.S Phase IIb trial in 50 patients showed that Actimmune 3 times a week with Infergen daily reduced viral load below the level of detection in 46% a...